NVCR News and Press, NovoCure Limited From 07/07/20

The last patient has been enrolled in Novocure's (NASDAQ: NVCR ) HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer. Final data collection will occur in six months. More news on: NovoCure Limited, Healt...

Final data collection will occur in six months Novocure (NASDAQ: NVCR) today announced that the last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer. The final data...

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2020 on Thursday, July 30, 2020, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the three and...

Novocure (NASDAQ: NVCR ) has launched MyLink, a new tool that allows patients to download their Optune usage data from the comfort of home. More news on: NovoCure Limited, Healthcare stocks news, Read more ...

Novocure (NASDAQ: NVCR) today announced the launch of MyLink, a new tool that allows patients to download their Optune usage data from the comfort of home without the need for an in-person visit by a Novocure Device Support Specialist. Novocure initiated a phased launch with an initial wave o...

COVID-19 Pandemic Sorrento Therapeutics (SRNE), a San Diego-China biotech, reported that its anti-SARS-CoV-2 antibody, STI-1499, completely inhibited SARS-CoV-2 virus infection from interacting with the ACE2 receptor after four days of incubation (see story ). In preclinical studies, the mo...

Optune is the first innovative treatment for glioblastoma approved in China in over 15 years A large, global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding Optune to chemotherapy more than doubled the five-year overall survival rat e 1 Optune is Za...

Investment thesis NovoCure (NVCR) has made impressive progress in developing and commercialising its novel and innovative Tumor Treating Fields therapy technology, which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division, administered via a head-wo...

Image source: The Motley Fool. NovoCure Limited   (NASDAQ: NVCR) Q1 2020 Earnings Call May 2, 2020 , 10:00 p.m. ET Operator Continue reading

Axcella Health (NASDAQ: AXLA ) initiated with Buy rating and $10 (115% upside) price target at BTIG Research. More news on: Axcella Health Inc., Viking Therapeutics, Inc., Y-mAbs Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...